Bedside to gene and back in idiopathic pulmonary fibrosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Molecular Mechanisms of Alveolar Epithelial Stem Cell Senescence and Senescence-Associated Differentiation Disorders in Pulmonary Fibrosis.Cells · 2022
   Review
2. Knockdown of long non‑coding RNA DLEU2 suppresses idiopathic pulmonary fibrosis by regulating the microRNA‑369‑3p/TRIM2 axis.International journal of molecular medicine · 2021
   Article
3. Upregulation of long noncoding RNA AP003419.16 predicts high risk of aging‑associated idiopathic pulmonary fibrosis.Molecular medicine reports · 2017
   Article
4. Idiopathic pulmonary fibrosis is strongly associated with productive infection by herpesvirus saimiri.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2014
   Article

Corrections and comments

• Comment on
  MUC5B promoter polymorphism and interstitial lung abnormalities.2013

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as